Published in Infect Immun on August 01, 1982
Cholera. Clin Microbiol Rev (1995) 12.33
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev (1992) 5.15
Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ (1985) 3.59
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Successful colonization and immunization of adult rabbits by oral inoculation with Vibrio cholerae O1. Infect Immun (1983) 1.67
Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding. J Exp Med (1988) 1.63
Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun (1993) 1.52
Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera. Infect Immun (1994) 1.46
Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1991) 1.42
Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect Immun (1987) 1.20
Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun (1983) 1.19
Protection in rabbits immunized with a vaccine of Escherichia coli heat-stable toxin cross-linked to the heat-labile toxin B subunit. Infect Immun (1983) 1.19
Determinants of immunogenicity and mechanisms of protection by virulent and mutant Vibrio cholerae O1 in rabbits. Infect Immun (1988) 1.10
Protective secretory immunoglobulin A antibodies in humans following oral immunization with Streptococcus mutans. Infect Immun (1987) 0.99
Compared colonizing and immunizing efficiency of toxinogenic (A+ B+) Vibrio cholerae and an A- B+ mutant (Texas Star-SR) studied in adult rabbits. Infect Immun (1984) 0.87
Differences in cross-protection in rats immunized with the B subunits of cholera toxin and Escherichia coli heat-labile toxin. Infect Immun (1984) 0.85
Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes. Infect Immun (1984) 0.83
Importance of ADP-ribosylation in the morphological changes of PC12 cells induced by cholera toxin. Infect Immun (1994) 0.82
The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine (Auckl) (2011) 0.82
Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera. PLoS One (2012) 0.81
Preparation of procoligenoids from Escherichia coli heat-labile enterotoxins. Infect Immun (1984) 0.78
Immunization with cholera toxin B subunit induces high-level protection in the suckling mouse model of cholera. PLoS One (2013) 0.78
Induction of rat secretory IgA antibodies against cholera toxin by a synthetic peptide. Immunology (1986) 0.77
Effect of nicotine on secretory component synthesis by secretory epithelial cells. Clin Diagn Lab Immunol (1996) 0.77
Characterization of a surface glycoprotein from Echinococcus multilocularis and its mucosal vaccine potential in dogs. PLoS One (2013) 0.77
Protection of rat intestine against cholera toxin challenge by monoclonal anti-idiotypic antibody immunization via enteral and parenteral routes. Infect Immun (1991) 0.77
Comparison of the reactivities and immunogenicities of procholeragenoid and the B subunit of cholera toxin in Thai volunteers. Infect Immun (1989) 0.75
Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect Immun (1975) 13.58
CHARACTERISTICS OF AN IMMUNE SYSTEM COMMON TO CERTAIN EXTERNAL SECRETIONS. J Exp Med (1965) 8.32
Preparation of the vascular permeability factor of Vibrio cholerae. J Bacteriol (1966) 5.26
Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J Exp Med (1975) 5.02
Actions of cholera toxin and the prevention and treatment of cholera. Nature (1981) 4.78
Experimental canine cholera. I. Development of the model. J Infect Dis (1969) 4.02
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc Natl Acad Sci U S A (1979) 3.17
Procholeragenoid: an aggregated intermediate in the formation of choleragenoid. J Immunol (1971) 2.98
The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats. J Exp Med (1978) 2.94
Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun (1976) 2.92
Vibriocidal and agglutinating antibody patterns in cholera patients. J Infect Dis (1966) 2.67
Protection against experimental cholera by antitoxin. J Infect Dis (1972) 2.21
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. J Infect Dis (1977) 2.13
Special features of the priming process for a secretory IgA response. B cell priming with cholera toxin. J Exp Med (1981) 2.00
Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera. Infect Immun (1978) 1.84
Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun (1975) 1.82
Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats. J Immunol (1980) 1.73
Local (immunoglobulin A) immune response by the intestine to cholera toxin and its partial suppression with combined systemic and intra-intestinal immunization. Infect Immun (1978) 1.52
Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation. Bull World Health Organ (1973) 1.31
Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect Immun (1979) 1.30
Antitoxic immunity to cholera in dogs immunized orally with cholera toxin. Infect Immun (1980) 1.21
Protection against experimental cholera by oral or parenteral immunization. Infect Immun (1979) 1.11
Intestinal immune response to cholera toxin: dependence on route and dosage of antigen for priming and boosting. Infect Immun (1980) 0.88
Differences in the response of rabbit small intestine to heat-labile and heat-stable enterotoxins of Escherichia coli. Infect Immun (1973) 8.47
Quality of hospital care for seriously ill children in less-developed countries. Lancet (2001) 7.08
Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J Exp Med (1975) 5.02
Vibrio cholerae enterotoxin and its mode of action. Bacteriol Rev (1971) 4.98
Identification of a novel rickettsial infection in a patient diagnosed with murine typhus. J Clin Microbiol (1994) 4.06
Stimulation of jejunal secretion by a crude Escherichia coli enterotixin. Gastroenterology (1972) 4.02
Cholera in Africa: lessons on transmission and control for Latin America. Lancet (1991) 3.36
M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. J Infect Dis (1986) 3.32
Genetic characterization and transovarial transmission of a typhus-like rickettsia found in cat fleas. Proc Natl Acad Sci U S A (1992) 3.18
Deactivation of cholera toxin by ganglioside. J Infect Dis (1971) 3.16
Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09
Typhus and typhuslike rickettsiae associated with opossums and their fleas in Los Angeles County, California. J Clin Microbiol (1992) 3.05
The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats. J Exp Med (1978) 2.94
Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis (1974) 2.73
Effect of intragastric glucose-electrolyte infusion upon water and electrolyte balance in Asiatic cholera. Gastroenterology (1968) 2.51
Effects of prostaglandins, theophylline, and cholera exotoxin upon transmucosal water and electrolyte movement in the canine jejunum. Gastroenterology (1971) 2.39
Differential inhibitory effects of cholera toxoids and ganglioside on the enterotoxins of Vibrio cholerae and Escherichia coli. J Exp Med (1973) 2.38
Rumen contents as a reservoir of enterohemorrhagic Escherichia coli. FEMS Microbiol Lett (1993) 2.36
Pathogenicity of Escherichia coli O157:H7 in the intestines of neonatal calves. Infect Immun (1997) 2.35
Stimulation of glycerol production in fat cells by cholera toxin. Nature (1970) 2.34
Replacement of water and electrolyte losses in cholera by an oral glucose-electrolyte solution. Ann Intern Med (1969) 2.28
Effect of Escherichia coli on fluid transport across canine small bowel. Mechanism and time-course with enterotoxin and whole bacterial cells. J Clin Invest (1973) 2.25
Acute undifferentiated human diarrhea in the tropics. II. Alterations in intestinal fluid and electrolyte movements. J Clin Invest (1971) 2.22
Protection against experimental cholera by antitoxin. J Infect Dis (1972) 2.21
Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. J Infect Dis (1977) 2.13
Murine typhus: updated roles of multiple urban components and a second typhuslike rickettsia. J Med Entomol (1994) 2.05
Experimental cholera. A canine model. Lancet (1966) 1.88
Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera. Infect Immun (1978) 1.84
Determinants of the localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized rats. J Immunol (1982) 1.81
Impact of rice based oral rehydration solution on stool output and duration of diarrhoea: meta-analysis of 13 clinical trials. BMJ (1992) 1.74
Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats. J Immunol (1980) 1.73
Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol (1974) 1.73
Successful colonization and immunization of adult rabbits by oral inoculation with Vibrio cholerae O1. Infect Immun (1983) 1.67
Water and electrolyte losses due to cholera in infants and small children: a recovery balance study. Pediatrics (1970) 1.64
Controlled comparison of tetracycline and furazolidone in cholera. Br Med J (1968) 1.59
Optimal antibiotic therapy in cholera. Bull World Health Organ (1968) 1.58
Molecular identification of rickettsia-like microorganisms associated with colonized cat fleas (Ctenocephalides felis). Insect Mol Biol (1994) 1.56
Oral fluid--a simple weapon against dehydration in diarrhoea: how it works and how to use it. WHO Chron (1977) 1.53
Role of cholera toxin in enteric colonization by Vibrio cholerae O1 in rabbits. Infect Immun (1985) 1.51
Intestinal antibodies. J Infect Dis (1978) 1.48
The current status of oral therapy in the treatment of acute diarrheal illness. Am J Clin Nutr (1978) 1.43
Efficacy of rice-based oral rehydration. Lancet (1996) 1.40
Probable gallbladder infection in convalescent cholera patients. Lancet (1967) 1.39
Preliminary results of a study of small intestinal water and solute movement in acute and convalescent human cholera. Indian J Med Res (1968) 1.32
Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol (2000) 1.32
Challenge of dogs with live enterotoxigenic Escherichia coli and effects of repeated challenges on fluid secretion in jejunal Thiry-Vella loops. J Infect Dis (1976) 1.30
Serum antibody responses of cattle following experimental infection with Escherichia coli O157:H7. Infect Immun (1996) 1.26
Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship. Proc Natl Acad Sci U S A (2001) 1.25
Detection of polymerase chain reaction-amplified malarial DNA in infected blood and individual mosquitoes. Exp Parasitol (1991) 1.24
Gastric acidity in cholera and noncholera diarrhoea. Bull World Health Organ (1972) 1.23
Convalescent carriers of Vibrio cholerae. Detection and detailed investigation. Ann Intern Med (1970) 1.23
Cellular dissemination of priming for a mucosal immune response to cholera toxin in rats. J Immunol (1981) 1.22
Antitoxic immunity to cholera in dogs immunized orally with cholera toxin. Infect Immun (1980) 1.21
Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect Immun (1987) 1.20
Immunity to experimental cholera. II. Secretory and humoral antitoxin response to local and systemic toxoid administration. J Infect Dis (1975) 1.20
Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc Natl Acad Sci U S A (1999) 1.19
Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun (1983) 1.19
Is a low-osmolarity ORS solution more efficacious than standard WHO ORS solution? J Pediatr Gastroenterol Nutr (1994) 1.19
Rice-based oral rehydration solution for treating diarrhoea. Cochrane Database Syst Rev (2000) 1.15
Protection against challenge with Escherichia coli heat-labile enterotoxin by immunization of rats with cholera toxin/toxoid. Infect Immun (1977) 1.13
Animals as a source of Escherichia coli pathogenic for human beings. J Am Vet Med Assoc (1994) 1.12
Determinants of immunogenicity and mechanisms of protection by virulent and mutant Vibrio cholerae O1 in rabbits. Infect Immun (1988) 1.10
Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun (1998) 1.09
Subcellular and taxonomic specificity of monoclonal antibodies to New World Leishmania. Am J Trop Med Hyg (1985) 1.09
Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect Immun (1997) 1.08
Clinical trials of improved oral rehydration salt formulations: a review. Bull World Health Organ (1994) 1.07
Management of acute diarrhea in children: lessons learned. Pediatr Infect Dis J (1993) 1.04
In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines. Int J Mol Med (1998) 1.03
Induction of optimal mucosal antibody responses: effects of age, immunization route(s), and dosing schedule in rats. Infect Immun (1984) 1.03
Immune response of the intestinal mucosa to cholera toxoid. J Infect Dis (1977) 1.02
Stimulation of glycogenolysis by purified cholera exotoxin in disrupted cells. Johns Hopkins Med J (1971) 1.02
CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect Immun (1999) 1.01
Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine (2001) 0.99
Parenteral immunization causes antigen-specific cell-mediated suppression of an intestinal IgA response. J Immunol (1983) 0.99
The use of Ringer's lactate in the treatment of children with cholera and acute noncholera diarrhoea. Bull World Health Organ (1972) 0.98
Systemic effects of parenteral cholera enterotoxin in dogs. J Lab Clin Med (1972) 0.97
Intestinal immunization with soluble bacterial antigens: the example of cholera toxoid. Ciba Found Symp (1976) 0.97
Oral-rehydration therapy--the role of polymeric substrates. N Engl J Med (1988) 0.95
Inhibition of malaria parasite development in mosquitoes by anti-mosquito-midgut antibodies. Infect Immun (1994) 0.92
Disseminated Curvularia infection. Additional therapeutic and clinical considerations with evidence of medical cure. Arch Pathol Lab Med (1986) 0.92
Effect of protein deprivation on immunoregulatory cells in the rat mucosal immune response. Clin Exp Immunol (1985) 0.92
Indicator dilution studies in the small bowel of patients with cholera diarrhea. II. Comparisons of absorbable and "poorly absorbable" substances. Johns Hopkins Med J (1970) 0.91
Magnitude and duration of antitoxic response to human infection with Vibrio cholerae. J Infect Dis (1970) 0.91
Identification and recovery of Leishmania antigen displayed on the surface membrane of mouse peritoneal macrophages infected in vitro. J Immunol (1986) 0.91
Protein deprivation causes reversible impariment of mucosal immune response to cholera toxoid/toxin in rat gut. Nature (1979) 0.89
Bacteriological studies of convalescent carriers of cholera vibrios. Indian J Med Res (1969) 0.89
Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine (1999) 0.88
Compared colonizing and immunizing efficiency of toxinogenic (A+ B+) Vibrio cholerae and an A- B+ mutant (Texas Star-SR) studied in adult rabbits. Infect Immun (1984) 0.87